Veradigm Inc. (MDRX)

Veradigm Inc. (MDRX) Healthcare & Pipeline Overview

Veradigm Inc. (MDRX) delivers comprehensive healthcare information technology solutions to providers, payers, and biopharma sectors globally. Specializing in electronic health records, practice management, revenue cycle management, and real-world data analytics, the company supports clinical and financial workflows, aiming to enhance healthcare efficiency and data utilization across its diverse client base.

What Is the Investment Thesis for MDRX?

Veradigm Inc. operates within the expanding healthcare technology market, driven by the ongoing digitization of healthcare and increasing demand for integrated data solutions. The company's comprehensive suite of offerings, spanning EHR, practice management, revenue cycle management, and real-world data analytics, positions it to capitalize on these trends. A key value driver is its extensive network and data assets, particularly in the biopharma sector, where real-world evidence is becoming increasingly critical for drug development and market access. The company's strategic shift and rebranding to Veradigm Inc. in January 2023 signals a renewed focus on data-driven solutions and interoperability, which could serve as a growth catalyst. However, the company's current financial performance, reflected in a -14.7% profit margin, indicates profitability challenges that require close monitoring. Its market capitalization of $865.28M, coupled with a gross margin of 52.5%, suggests a strong core business but operational inefficiencies or significant investment costs impacting the bottom line. The company's listing on the OTC Other tier presents risks related to liquidity and disclosure, which could affect investor confidence and capital access. Future growth will depend on its ability to enhance profitability, navigate the competitive healthcare IT landscape, and potentially transition to a major exchange to improve market visibility and liquidity.

Based on FMP financials and quantitative analysis

MDRX Key Highlights

• Market capitalization stands at $0.82 billion, reflecting its valuation within the healthcare technology sector.
• Gross margin of 52.5% indicates a strong core business model and efficient cost of goods sold.
• Profit margin of -14.7% highlights current profitability challenges, suggesting significant operational expenses or investment phases.
• The company operates with a Beta of 0.52, indicating lower volatility compared to the broader market.
• No dividend yield is reported, consistent with a growth-focused or reinvestment-heavy business strategy.

Who Are MDRX's Competitors?

MDRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MDRX's Key Strengths?

• Comprehensive suite of healthcare IT solutions across providers, payers, and biopharma.
• Strong position in real-world data and evidence, a growing segment for biopharma.
• Established client base and long operating history in the healthcare technology sector.
• High gross margin of 52.5% indicates efficient core operations.

What Are MDRX's Weaknesses?

• Negative profit margin of -14.7% indicates current unprofitability.
• Listing on the OTC Other tier suggests heightened risk and reduced liquidity.
• "Disclosure Status: Unknown" for OTC listing implies potential transparency issues.
• Requires significant investment to maintain competitive edge in rapidly evolving tech landscape.

What Could Drive MDRX Stock Higher?

• Potential uplisting to a higher OTC tier or major exchange, which could improve liquidity and investor visibility.
• Continued innovation and adoption of AI Patient Scheduling Software and other AI-driven solutions to enhance market competitiveness.
• Expansion of real-world data and evidence offerings to biopharma clients, capitalizing on increasing industry demand.
• Strategic initiatives to improve profitability and operational efficiency, aiming to reverse the current negative profit margin.

What Are the Key Risks for MDRX?

• Negative return on equity (-7.1%) — the business is not currently generating profit on shareholder capital.
• Challenges in achieving profitability, as evidenced by the -14.7% profit margin.
• Heightened liquidity and transparency risks associated with its OTC Other tier listing and "Unknown" disclosure status.
• Intense competition in the healthcare IT market from larger, more established players and agile startups.
• Regulatory changes in healthcare data privacy, interoperability, and reimbursement policies impacting its business model.
• Cybersecurity threats and data breaches, which could damage reputation and incur significant financial penalties.

What Are the Growth Opportunities for MDRX?

• Expansion in AI-Powered Healthcare Solutions: The global AI in healthcare market is projected to grow significantly, with estimates reaching over $100 billion by 2030. Veradigm's existing AI Patient Scheduling Software provides a foundation for expanding its artificial intelligence capabilities across its product suite. By integrating AI into areas like predictive analytics for risk adjustment, personalized patient engagement, and enhanced revenue cycle management, Veradigm can offer more sophisticated and efficient solutions. This expansion could attract new clients and deepen relationships with existing ones, leveraging its extensive data sets for competitive advantage within the next 3-5 years.
• Increased Demand for Real-World Data (RWD) in Biopharma: The biopharmaceutical industry's reliance on real-world data and evidence (RWE) for drug development, regulatory submissions, and post-market surveillance is rapidly increasing. The RWE market is expected to exceed $2 billion by 2027. Veradigm's real-world data solutions, including health data sets and specialized registries (cardiology, metabolic), position it to capitalize on this trend. By further developing its Real World Evidence Analytics Platform and therapy-focused data offerings, Veradigm can become a more critical partner for biopharma companies seeking insights into drug efficacy, safety, and market access, driving revenue growth over the next 5-7 years.
• Enhancing Interoperability and Data Exchange: The healthcare industry is moving towards greater interoperability, with initiatives like the 21st Century Cures Act driving the need for seamless data exchange. The market for healthcare interoperability solutions is anticipated to reach over $7 billion by 2028. Veradigm's API connectivity solutions, such as Veradigm Connect and the Diagnostic Ordering and Resulting Network, are crucial assets in this environment. Expanding these platforms to facilitate more robust and secure data sharing between providers, payers, and patients can enhance its competitive position, making its ecosystem more attractive and sticky for clients, with significant impact expected within 2-4 years.
• Growth in Payer-Focused Risk Adjustment and Quality Management: Health plans and payers face increasing pressure to manage costs, improve quality outcomes, and accurately assess risk. The market for healthcare analytics, including risk adjustment, is projected to grow substantially, reaching tens of billions globally by the end of the decade. Veradigm's comprehensive suite of risk adjustment solutions (e.g., Health Equity Analytics, Risk Mitigator) and quality management tools directly addresses these critical payer needs. By continuously innovating and demonstrating tangible ROI for payers, Veradigm can expand its footprint in this segment, securing long-term contracts and recurring revenue streams over the next 3-6 years.
• Expansion of Revenue Cycle Management (RCM) Services: Healthcare providers increasingly seek outsourced or technology-enabled solutions to optimize their revenue cycles amidst rising administrative complexities and declining reimbursement rates. The global RCM market is expected to reach over $100 billion by 2030. Veradigm's Revenue Cycle Services and clearinghouse solutions offer a strong foundation. By enhancing these offerings with advanced automation, AI-driven denial management, and predictive analytics, Veradigm can help providers improve financial performance, reduce administrative burden, and ensure compliance, thereby capturing a larger share of this growing market over the next 4-6 years.

What Opportunities Does MDRX Have?

• Increasing demand for AI-driven healthcare solutions and interoperability.
• Growing reliance on real-world data for drug development and regulatory insights.
• Expansion into new geographic markets or specialized healthcare segments.
• Potential to improve profitability through operational efficiencies and scaling solutions.

What Threats Does MDRX Face?

• Intense competition from established healthcare IT giants and agile startups.
• Regulatory changes impacting data privacy, interoperability, and healthcare reimbursement.
• Cybersecurity risks and data breaches, which could erode client trust and incur significant costs.
• Economic downturns impacting healthcare spending and technology adoption rates.

What Are MDRX's Competitive Advantages?

• Extensive Data Assets: Proprietary access to a vast repository of real-world health data, particularly valuable for biopharma research and payer analytics.
• Integrated Solutions Portfolio: Offers a comprehensive suite of IT solutions across providers, payers, and biopharma, creating a sticky ecosystem for clients.
• Established Market Presence: Long operating history since 1986 and established relationships with a broad client base in the healthcare sector.
• Interoperability Capabilities: API connectivity solutions like Veradigm Connect facilitate data exchange, enhancing its value proposition in an increasingly interconnected healthcare landscape.

What Does MDRX Do?

Founded in 1986, Veradigm Inc., formerly known as Allscripts Healthcare Solutions, Inc. until its name change in January 2023, has evolved into a significant player in the healthcare technology sector. Headquartered in Chicago, Illinois, the company provides a broad spectrum of information technology solutions to healthcare providers, payers, and biopharma markets, primarily in the United States but also internationally. For healthcare providers, Veradigm offers essential tools such as Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments to streamline administrative and patient interaction processes. Its revenue cycle management portfolio includes comprehensive Revenue Cycle Services and a dedicated clearinghouse, designed to optimize financial performance for medical practices. The company is also a key provider of electronic health records (EHR) solutions, featuring ePrescribe with EPCS, general EHR software, Veradigm HER, and Practice Fusion HER, which are critical for clinical documentation and patient care coordination. A Patient Engagement Platform further enhances communication and interaction between providers and patients. Beyond direct provider solutions, Veradigm extends its offerings to network partners through API connectivity solutions like Veradigm Connect, Veradigm App Expo, and a Diagnostic Ordering and Resulting Network, fostering interoperability within the healthcare ecosystem. A Channel Partner Program and Veradigm ePrescribe Enterprise further expand its reach. For health plans and payers, Veradigm delivers sophisticated risk adjustment solutions, including Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics, helping manage population health and financial risk. Quality management solutions, such as quality analytics and integrated risk adjustment and quality management, are also provided. Data exchange and coding solutions like eChart Courier, eChart Coder, and eChart Integration and Analytics, alongside provider engagement tools and Veradigm Payer Insights, support efficient data flow and payer-provider collaboration. The Veradigm Payerpath solutions further bolster this segment. In the biopharma sector, Veradigm leverages its extensive data assets to offer real-world data solutions, including diverse real-world and health data sets, and specialized cardiology and metabolic registries. Its Real World Evidence Analytics Platform supports research and development, while therapy-focused solutions provide granular data for areas like cardiovascular, central nervous system, metabolic, and immunology. Digital Health Media solutions complete its biopharma portfolio, demonstrating its comprehensive approach to healthcare technology across multiple market segments.

What Products and Services Does MDRX Offer?

• Develops and sells software for managing medical practices, including patient scheduling and electronic payments.
• Provides Electronic Health Records (EHR) systems like Veradigm HER and Practice Fusion HER for clinical documentation and e-prescribing.
• Offers revenue cycle management services and clearinghouse solutions to help healthcare providers manage billing and collections.
• Connects healthcare systems through API solutions, enabling data exchange between providers and partners.
• Supplies health plans and payers with analytics tools for risk adjustment, quality management, and data exchange.
• Delivers real-world data sets and evidence platforms to biopharmaceutical companies for research and development.
• Provides therapy-focused data solutions across various medical areas, including cardiovascular and immunology.
• Offers Digital Health Media solutions, likely for patient engagement and educational content.

How Does MDRX Make Money?

• Sells software licenses and subscriptions for its various healthcare IT solutions to providers, payers, and biopharma companies.
• Generates revenue from professional services related to implementation, support, and consulting for its software platforms.
• Earns fees for processing transactions through its revenue cycle management clearinghouse and data exchange services.
• Monetizes its extensive real-world data sets by providing access and analytical insights to biopharma clients.

What Industry Does MDRX Operate In?

Veradigm Inc. operates in the dynamic Medical - Healthcare Information Services industry, a sector characterized by rapid technological advancements and increasing regulatory demands. The broader healthcare IT market is experiencing robust growth, fueled by the global push for digital transformation in healthcare, the need for improved patient outcomes, and the rising complexity of healthcare administration and data management. Key trends include the adoption of AI-driven solutions for patient scheduling, the expansion of interoperable EHR systems, and the growing importance of real-world data for pharmaceutical research and payer risk adjustment. Veradigm's comprehensive portfolio, which spans provider, payer, and biopharma solutions, positions it to address multiple facets of this evolving market. However, the industry is highly competitive, with established players and innovative startups vying for market share, necessitating continuous innovation and strategic partnerships for sustained growth.

Who Are MDRX's Key Customers?

• Healthcare providers, including physician practices and hospitals, utilizing EHR and practice management software.
• Health plans and payers, leveraging risk adjustment, quality management, and data exchange solutions.
• Biopharmaceutical companies, accessing real-world data, evidence platforms, and therapy-focused insights.
• Network partners, integrating through API connectivity solutions and channel programs.

How Veradigm Inc. Is Valued

Veradigm Inc. carries a market capitalization of $865.28M, placing it in the small-cap category. Relative to its peer group, MDRX's quantitative score of 50/100 is below the peer average of 64/100.

Company Profile

Veradigm Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO Donald D. Trigg. MDRX has traded publicly since 1999.

ROE -7%Key Financial Metrics

Return on equity for Veradigm Inc. stands at -7.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 9.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.95 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Veradigm Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.78 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project Veradigm Inc. revenue of about $583.2M for fiscal 2026, with EPS near $0.30.

Net buyingInsider Activity

Over the past six months, Veradigm Inc. insiders filed 7 SEC Form 4 transactions — 1 sales and 6 purchases. On net that is roughly 1.0M shares acquired (about $7K) — insiders putting money in tends to read as conviction.

MDRX Financials

MDRX Latest News

MDRX Analyst Consensus

MDRX MoonshotScore

What Investors Ask About Veradigm Inc. (MDRX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources